Most patients with advanced renal cancer develop drug resistance to targeted drugs, and the disease progresses with the prolongation of the treatment cycle. Therefore, it is necessary to explore new treatment methods for advanced renal cancer to obtain continuous efficacy and prolong the survival time of patients. The patient was diagnosed with advanced renal cancer that had progressed after previous antiangiogenic drug therapy, based on the clinical course and imaging findings. The patient was treated with 'tislelizumab plus apatinib'. The clinical discomfort symptoms were quickly relieved after treatment, and the evaluation two cycles later showed stable disease. After two cycles of continuation of the original regimen, reevaluation CT demonstrated a significant reduction in the size of the abdominal cavity mass and the therapeutic evaluation was partial remission after four cycles; however, the patient developed abnormal liver function after treatment, manifested as nausea and poor appetite, and significantly increased bilirubin and transaminase levels, which were considered as immune-related liver injuries. After glucocorticoid treatment, the patient's condition quickly improved and recovered. This report is the first to suggest a potential approach to advanced renal clear cell carcinoma and describes the effects of immunocombination therapy on advanced renal clear cell carcinoma; the results showed the current stage success of the immunocombination treatment, suggesting that this treatment may be an effective treatment option for patients with advanced renal clear cell carcinoma. In addition, the toxic and side effects of combined immunotherapy need to be carefully identified by every doctor. Since only one patient with advanced renal cancer was observed in this report, the clinical data are very limited and further observation and accumulation of more experience are needed, and further clinical studies will be conducted on the efficacy and safety of this combination regimen.

中文翻译：

---

替雷利珠单抗联合阿帕替尼治疗晚期肾透明细胞癌一例报告。

大多数晚期肾癌患者对靶向药物产生耐药性，且病情随着治疗周期的延长而进展。因此，有必要探索晚期肾癌新的治疗方法，以获得持续疗效，延长患者的生存时间。根据临床病程和影像学检查结果，该患者被诊断为晚期肾癌，且在先前的抗血管生成药物治疗后病情进展。该患者接受“替雷利珠单抗加阿帕替尼”治疗。治疗后临床不适症状迅速缓解，两个周期后评估病情稳定。继续原方案两个周期后，重新评估CT显示腹腔肿块大小显着减小，四个周期后治疗评估部分缓解；但患者治疗后出现肝功能异常，表现为恶心、食欲不佳，胆红素、转氨酶水平明显升高，考虑为免疫相关性肝损伤。经过糖皮质激素治疗后，患者病情迅速好转并康复。该报告首次提出了一种治疗晚期肾透明细胞癌的潜在方法，并描述了免疫组合疗法对晚期肾透明细胞癌的效果；结果显示了免疫联合治疗目前阶段的成功，表明这种治疗可能是晚期肾透明细胞癌患者的有效治疗选择。此外，联合免疫疗法的毒副作用需要每位医生仔细辨别。由于本报告仅观察了1例晚期肾癌患者，因此临床数据非常有限，需要进一步观察和积累更多经验，并将对该联合方案的有效性和安全性进行进一步的临床研究。